His primary areas of investigation include Internal medicine, Lung cancer, Oncology, Surgery and Radiology. His Internal medicine research incorporates elements of Gastroenterology and Endocrinology. His Lung cancer research is multidisciplinary, incorporating perspectives in Cancer, Clinical trial, Incidence, Randomized controlled trial and Lung.
His work in the fields of Adenocarcinoma and Atezolizumab overlaps with other areas such as Monoclonal. The concepts of his Oncology study are interwoven with issues in Carboplatin, Clinical endpoint, Pharmacology and Circulating tumor cell. His Surgery study integrates concerns from other disciplines, such as Quality and Adverse effect.
His primary scientific interests are in Internal medicine, Lung cancer, Oncology, Surgery and Cancer research. His Internal medicine study frequently links to adjacent areas such as Gastroenterology. His work carried out in the field of Lung cancer brings together such families of science as Cancer, Adenocarcinoma and Radiology, Radiation therapy.
Harry J.M. Groen interconnects Stage and Lung in the investigation of issues within Radiology. His Oncology study deals with Carboplatin intersecting with Bevacizumab. As part of his studies on Surgery, Harry J.M. Groen often connects relevant areas like Clinical trial.
Lung cancer, Internal medicine, Oncology, Cancer research and Non small cell are his primary areas of study. His Lung cancer research is multidisciplinary, incorporating elements of Lung, Radiology, Circulating tumor cell and Adenocarcinoma. In the subject of general Internal medicine, his work in Chemotherapy, Cancer and Conventional PCI is often linked to In patient, thereby combining diverse domains of study.
Harry J.M. Groen has included themes like Positron emission tomography, Biopsy, Clinical trial and Carcinoma in his Cancer study. His work deals with themes such as Phases of clinical research and Hazard ratio, which intersect with Oncology. His Cancer research research includes elements of Pd l1 expression, Immune checkpoint inhibitors, Predictive biomarker, Gefitinib and Crizotinib.
Harry J.M. Groen mainly focuses on Lung cancer, Internal medicine, Oncology, non-small cell lung cancer and Radiology. His Lung cancer research is mostly focused on the topic Erlotinib. His research on Internal medicine often connects related topics like Gastroenterology.
His study in Oncology is interdisciplinary in nature, drawing from both Cancer, Adverse effect, Biodistribution and Hazard ratio. His biological study spans a wide range of topics, including Brain lesions and Capmatinib. His research in Radiology intersects with topics in Lung, Incidence and Disease.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials
Joe Y Chang;Suresh Senan;Marinus A. Paul;Reza John Mehran.
Lancet Oncology (2015)
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer
Martin Peifer;Lynnette Fernández-Cuesta;Martin L. Sos;Julie George.
Nature Genetics (2012)
Multiple common variants for celiac disease influencing immune gene expression
Patrick C. A. Dubois;Gosia Trynka;Lude Franke;Lude Franke;Karen A. Hunt.
Nature Genetics (2010)
Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer
Jonathan Weiss;Martin L. Sos;Danila Seidel;Martin Peifer.
Science Translational Medicine (2010)
Management of lung nodules detected by volume CT scanning
Rob J van Klaveren;Matthijs Oudkerk;Mathias Prokop;Ernst T Scholten.
The New England Journal of Medicine (2009)
Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
David Planchard;Egbert F Smit;Harry J M Groen;Julien Mazieres.
Lancet Oncology (2016)
Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer
Peter S. Hammerman;Martin L. Sos;Alex H. Ramos;Chunxiao Xu.
Cancer Discovery (2011)
A genomics-based classification of human lung tumors
Danila Seidel;Thomas Zander;Lukas C. Heukamp;Martin Peifer.
Science Translational Medicine (2013)
Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial
Harry J de Koning;Carlijn M van der Aalst;Pim A de Jong;Ernst T Scholten.
The New England Journal of Medicine (2020)
Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial
Dong Wan Kim;Dong Wan Kim;Marcello Tiseo;Myung Ju Ahn;Karen L. Reckamp.
Journal of Clinical Oncology (2017)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: